Detailed Information

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

DC Field Value Language
dc.contributor.authorKim, B. -S.-
dc.contributor.authorKim, D. -W.-
dc.contributor.authorIm, S. -A.-
dc.contributor.authorKim, C. W.-
dc.contributor.authorKim, T. -Y.-
dc.contributor.authorYoon, S. -S.-
dc.contributor.authorHeo, D. S.-
dc.contributor.authorBang, Y. -J.-
dc.contributor.authorPark, S.-
dc.contributor.authorKim, B. K.-
dc.contributor.authorKim, N. K.-
dc.identifier.citationAnnals of Oncology, Vol.20 No.1, pp.121-128-
dc.description.abstractBackground: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.-
dc.publisherOxford University Press-
dc.titleEffective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone-
dc.citation.journaltitleAnnals of Oncology-
dc.description.citedreferenceLee KW, 2006, LEUKEMIA LYMPHOMA, V47, P1274, DOI 10.1080/10428190600562823-
dc.description.citedreferenceKim HJ, 2006, BONE MARROW TRANSPL, V37, P819, DOI 10.1038/sj.bmt.1705349-
dc.description.citedreferenceSuzuki R, 2006, BONE MARROW TRANSPL, V37, P425, DOI 10.1038/sj.bmt.1705244-
dc.description.citedreferenceKim TM, 2005, BLOOD, V106, P3785-
dc.description.citedreferenceYou JY, 2004, ANN ONCOL, V15, P618, DOI 10.1093/annonc/mdh143-
dc.description.citedreferenceLi CC, 2004, CANCER, V100, P366, DOI 10.1002/cncr.11908-
dc.description.citedreferenceChim CS, 2004, BLOOD, V103, P216, DOI 10.1182/blood-2003-05-1401-
dc.description.citedreferenceKim BS, 2003, ACTA ONCOL, V42, P779, DOI 10.1080/02841860310010682-
dc.description.citedreferenceYong WB, 2003, INT J HEMATOL, V78, P163-
dc.description.citedreferenceMatsumoto Y, 2003, LEUKEMIA LYMPHOMA, V44, P879, DOI 10.1080/1042819031000067873-
dc.description.citedreferenceNagafuji K, 2001, INT J HEMATOL, V74, P447-
dc.description.citedreferenceShikama N, 2001, INT J RADIAT ONCOL, V51, P1228-
dc.description.citedreferenceRibrag V, 2001, LEUKEMIA, V15, P1123-
dc.description.citedreferenceKim WS, 2001, ANN ONCOL, V12, P349-
dc.description.citedreferenceYAMAGUCHI M, 2001, J CLIN EXP HEMATOPAT, V41, P93-
dc.description.citedreferenceRodriguez J, 2000, LEUKEMIA LYMPHOMA, V39, P139-
dc.description.citedreferenceKim GE, 2000, J CLIN ONCOL, V18, P54-
dc.description.citedreferenceKo YH, 1998, CANCER, V83, P806-
dc.description.citedreferenceLi YX, 1998, CANCER, V83, P449-
dc.description.citedreferenceCheung MMC, 1998, J CLIN ONCOL, V16, P70-
dc.description.citedreferenceLogsdon MD, 1997, CANCER, V80, P477-
dc.description.citedreferenceShikama N, 1997, RADIOLOGY, V204, P467-
dc.description.citedreferenceKwong YL, 1997, BRIT J HAEMATOL, V97, P821-
dc.description.citedreferenceCHAN JKC, 1997, BLOOD, V9, P4501-
dc.description.citedreferenceJaffe ES, 1996, AM J SURG PATHOL, V20, P103-
dc.description.citedreferenceChen HHW, 1996, RADIOTHER ONCOL, V38, P1-
dc.description.citedreferenceLIANG R, 1995, J CLIN ONCOL, V13, P666-
dc.description.citedreferenceCHAN JKC, 1994, AM J SURG PATHOL, V18, P938-
dc.description.citedreferenceVELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169-
dc.description.citedreferenceARBER DA, 1993, AM J SURG PATHOL, V17, P392-
dc.description.citedreferenceSOBREVILLACALVO P, 1993, ACTA ONCOL, V32, P69-
dc.description.citedreferenceSMALLEY SR, 1988, INT J RADIAT ONCOL, V15, P599-
dc.description.citedreferenceVELASQUEZ WS, 1988, BLOOD, V71, P117-
dc.description.citedreferenceCABANILLAS F, 1982, BLOOD, V60, P693-
dc.contributor.affiliatedAuthorKim, D. -W.-
dc.contributor.affiliatedAuthorIm, S. -A.-
dc.contributor.affiliatedAuthorKim, C. W.-
dc.contributor.affiliatedAuthorKim, T. -Y.-
dc.contributor.affiliatedAuthorYoon, S. -S.-
dc.contributor.affiliatedAuthorHeo, D. S.-
dc.contributor.affiliatedAuthorBang, Y. -J.-
dc.contributor.affiliatedAuthorKim, B. K.-
dc.subject.keywordPlusNATURAL KILLER/T-CELL-
dc.subject.keywordPlusUPPER AERODIGESTIVE TRACT-
dc.subject.keywordPlusNASAL CAVITY-
dc.subject.keywordPlusPOLYMORPHIC RETICULOSIS-
dc.subject.keywordPlusANGIOCENTRIC LYMPHOMA-
dc.subject.keywordAuthorNK/T-cell lymphoma-
dc.subject.keywordAuthorSalvage chemotherapy-
dc.subject.keywordAuthorSecond-line chemotherapy-
Appears in Collections:
Files in This Item:
There are no files associated with this item.


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.